Axogen Inc vs JPMorgan Nasdaq Equity Premium Income ETF — how do they compare? Axogen Inc trades at $49.66 (market cap $2.61B), while JPMorgan Nasdaq Equity Premium Income ETF trades at $59.99. The key difference: Axogen Inc is trading nearer its 52-week high, JPMorgan Nasdaq Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| AXGN | JEPQ | |
|---|---|---|
Market Cap | $2.61B | — |
Sector | Technology | Income / Options Overlay |
52-Week High | $48.48 | $61.46 |
52-Week Low | $14.16 | $53.77 |
Enterprise Value | $2.52B | — |
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $49.67, up 3.01% with strong technical momentum. The stock shows bullish moving average signals despite recent earnings misses. Q2 2026 revenue grew 23.1% to $69.7M with raised full-year guidance to $279M, though net margins remain negative at -13.36%. Analyst consensus is strongly bullish with 16 buy ratings and $54.33 price target.
Growth prospects appear strong with expanding nerve care platform and reimbursement wins, but profitability challenges and high valuation multiples present risks. The stock trades near resistance at $50 with RSI indicating overbought conditions, suggesting potential near-term consolidation before further upside.
JEPQ trades at $60.00, up 0.54% with a bullish technical signal from moving averages. The ETF's covered-call strategy generates monthly income, with recent dividends of $0.70, $0.64, and $0.56. News highlights focus on retirement income strategies and tax implications of distributions. Institutional interest remains strong, with Bank of America increasing its stake by 8.9% in Q1 2026.
Outlook remains positive for income-focused investors, though the RSI suggests potential overbought conditions. Key risks include tax treatment of distributions and market volatility affecting the options strategy. The fund's $39 billion AUM and active management support its popularity for yield generation in retirement portfolios.
Trailing returns across standard periods
Latest headlines on both assets
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →